{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:40:53Z","timestamp":1784756453905,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular features of these rare tumors was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multicenter retrospective national study was performed within the French TMRG (Rare Gynecologic Malignant Tumors) network. Clinical data and, when available, FFPE blocks were collected. Clinical features, treatments, and outcome (progression-free survival (PFS) and overall survival (OS)) were analyzed and correlated to the protein (tissue micro-array), RNA (Nanostring nCounter<jats:sup>\u00ae<\/jats:sup> technology), and DNA (array-Comparative Genomic hybridization and target-next generation sequencing) levels using the tumor samples available.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-eight patients with uterine CCC were enrolled, 61 from endometrial localization and 5 with cervix localization. Median age at diagnosis was 68.9\u00a0years old (range 19\u201389.7). Most tumors were diagnosed at an early stage (78% FIGO stage I\u2013II). Hysterectomy (performed in 90%) and lymph node dissection (80%) were the most frequent surgical treatment. More than 70% of patients received external beam radiotherapy and 57% received brachytherapy. Nearly half (46%) of the patients received chemotherapy. After a median follow-up of 24.7\u00a0months, median PFS was 64.8\u00a0months (95 CI [5.3\u2013124.4]) and median OS was 79.7 (IC95 [31.0\u2013128.4]). Low hormone receptor expression (13% estrogen-receptor positive), frequent PI3K pathway alterations (58% PTEN loss, 50% <jats:italic>PIK3CA<\/jats:italic> mutations), and P53 abnormalities (41%) were observed. Mismatch repair deficiency was identified in 20%. P16 expression was associated with shorter PFS (HR\u2009=\u20095.88, 95 CI [1.56\u201325], <jats:italic>p<\/jats:italic>\u2009=\u20090.009). Transcriptomic analyzes revealed a specific transcriptomic profile notably with a high expression of immune response-associated genes in uterine CCC displaying a very good overall prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Uterine CCC reported to be potentially MSI high, hormone receptors negative, and sometimes <jats:italic>TP53<\/jats:italic> mutated. However, some patients with immune response-associated features and better prognosis may be candidate to treatment de-escalation and immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04264-7","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T08:54:43Z","timestamp":1687510483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network"],"prefix":"10.1186","volume":"21","author":[{"given":"Elsa","family":"Nigon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lefeuvre-Plesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Chauleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Guille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ad\u00e9la\u00cfde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Finetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoire","family":"de Casteljac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Mamessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-682X","authenticated-orcid":false,"given":"Renaud","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"4264_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ygyno.2009.02.003","volume":"113","author":"AB Olawaiye","year":"2009","unstructured":"Olawaiye AB, Boruta DM. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;113:277\u201383.","journal-title":"Gynecol Oncol"},{"key":"4264_CR2","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2229::AID-CNCR22>3.0.CO;2-X","volume":"79","author":"A Hanselaar","year":"1997","unstructured":"Hanselaar A, van Loosbroek M, Schuurbiers O, Helmerhorst T, Bulten J, Bernhelm J. Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks. Cancer. 1997;79:2229\u201336.","journal-title":"Cancer"},{"key":"4264_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ygyno.2022.01.012","volume":"164","author":"G Bogani","year":"2022","unstructured":"Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Clear cell carcinoma of the endometrium. Gynecol Oncol. 2022;164:658\u201366.","journal-title":"Gynecol Oncol"},{"key":"4264_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732782","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Gao P, Bao Z, Zeng L, Yao J, Chai D, et al. Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in 27 cases. Front Oncol. 2021;11: 732782.","journal-title":"Front Oncol"},{"key":"4264_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.humpath.2019.06.005","volume":"92","author":"GF Zannoni","year":"2019","unstructured":"Zannoni GF, Santoro A, Angelico G, Spadola S, Arciuolo D, Valente M, et al. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases. Hum Pathol. 2019;92:10\u20137.","journal-title":"Hum Pathol"},{"key":"4264_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0046-8177(98)80002-6","volume":"29","author":"SF Lax","year":"1998","unstructured":"Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551\u20138.","journal-title":"Hum Pathol"},{"key":"4264_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1746-1596-3-6","volume":"3","author":"O Fadare","year":"2008","unstructured":"Fadare O, Zheng W. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol. 2008;3:6.","journal-title":"Diagn Pathol"},{"key":"4264_CR8","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1097\/IGC.0000000000000297","volume":"24","author":"K Hasegawa","year":"2014","unstructured":"Hasegawa K, Nagao S, Yasuda M, Millan D, Viswanathan AN, Glasspool RM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer. 2014;24:S90-95.","journal-title":"Int J Gynecol Cancer"},{"key":"4264_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ygyno.2019.12.046","volume":"157","author":"A Chevrot","year":"2020","unstructured":"Chevrot A, Pouget N, Bats A-S, Huchon C, Guyon F, Chopin N, et al. Fertility and prognosis of borderline ovarian tumor after conservative management: results of the multicentric OPTIBOT study by the GINECO & TMRG group. Gynecol Oncol. 2020;157:29\u201335.","journal-title":"Gynecol Oncol"},{"key":"4264_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ygyno.2020.06.491","volume":"158","author":"F Derquin","year":"2020","unstructured":"Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, et al. Need for risk-adapted therapy for malignant ovarian germ cell tumors: a large multicenter analysis of germ cell tumors\u2019 patients from French TMRG network. Gynecol Oncol. 2020;158:666\u201372.","journal-title":"Gynecol Oncol"},{"key":"4264_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/cancers14020354","volume":"14","author":"C Romeo","year":"2022","unstructured":"Romeo C, Le Saux O, Jacobs M, Joly F, Ferron G, Favier L, et al. Therapeutic challenges in patients with gynecologic carcinosarcomas: analysis of a multicenter national cohort study from the French prospective TMRG network. Cancers (Basel). 2022;14:354.","journal-title":"Cancers (Basel)"},{"key":"4264_CR12","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38:1346\u201366.","journal-title":"J Clin Oncol"},{"key":"4264_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153383","volume":"220","author":"N Ida","year":"2021","unstructured":"Ida N, Nakamura K, Saijo M, Nasu A, Yoshino T, Masuyama H, et al. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component. Pathol Res Pract. 2021;220: 153383.","journal-title":"Pathol Res Pract"},{"key":"4264_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euo.2018.02.006","volume":"1","author":"P Rescigno","year":"2018","unstructured":"Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, et al. Docetaxel treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur Urol Oncol. 2018;1:71\u20137.","journal-title":"Eur Urol Oncol"},{"key":"4264_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/modpathol.2011.208","volume":"25","author":"B Djordjevic","year":"2012","unstructured":"Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012;25:699\u2013708.","journal-title":"Mod Pathol"},{"key":"4264_CR16","unstructured":"Chung Y, Lee HW, Park JH, Yoo CH, Son BH, Kim K. Mutant pattern of p53 predicts local recurrence and poor survival rate in gastric cancer. Histol Histopathol. 2023;18596."},{"key":"4264_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.5373","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of \u201cmultiple-classifier\u201d endometrial carcinomas. J Pathol. 2020;250:312\u201322.","journal-title":"J Pathol"},{"key":"4264_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14737159.2017.1268533","volume":"17","author":"HF Tsang","year":"2017","unstructured":"Tsang HF, Xue VW, Koh SP, Chiu YM, Ng LPW, Wong SCC. NanoString, a novel digital color-coded barcode technology current and future applications in molecular diagnostics. Expert Rev Mol Diagn. 2017;17:95\u2013103.","journal-title":"Expert Rev Mol Diagn"},{"key":"4264_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2016.02.023","volume":"141","author":"B Winterhoff","year":"2016","unstructured":"Winterhoff B, Hamidi H, Wang C, Kalli KR, Fridley BL, Dering J, et al. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol Oncol. 2016;141:95\u2013100.","journal-title":"Gynecol Oncol"},{"key":"4264_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3817","author":"KL Bolton","year":"2022","unstructured":"Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, K\u00f6bel M, et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3817.","journal-title":"Clin Cancer Res"},{"key":"4264_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67\u201373.","journal-title":"Nature"},{"key":"4264_CR22","doi-asserted-by":"publisher","first-page":"79428","DOI":"10.18632\/oncotarget.12714","volume":"7","author":"A Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, et al. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget. 2016;7:79428\u201341.","journal-title":"Oncotarget"},{"key":"4264_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-021-00897-9","volume":"13","author":"F Bertucci","year":"2021","unstructured":"Bertucci F, Gon\u00e7alves A, Guille A, Adela\u00efde J, Garnier S, Carbuccia N, et al. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Med. 2021;13:87.","journal-title":"Genome Med"},{"key":"4264_CR24","doi-asserted-by":"publisher","first-page":"27208","DOI":"10.18632\/oncotarget.8349","volume":"7","author":"F Bertucci","year":"2016","unstructured":"Bertucci F, Finetti P, Guille A, Ad\u00e9la\u00efde J, Garnier S, Carbuccia N, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget. 2016;7:27208\u201319.","journal-title":"Oncotarget"},{"key":"4264_CR25","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2012.451","volume":"107","author":"V Abkevich","year":"2012","unstructured":"Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107:1776\u201382.","journal-title":"Br J Cancer"},{"key":"4264_CR26","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1073\/pnas.95.25.14863","volume":"95","author":"MB Eisen","year":"1998","unstructured":"Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4264_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","volume":"22","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics. 2006;22:1540\u20132.","journal-title":"Bioinformatics"},{"key":"4264_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"4264_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118\u201327.","journal-title":"Biostatistics"},{"key":"4264_CR30","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1093\/bioinformatics\/btr529","volume":"27","author":"J Taminau","year":"2011","unstructured":"Taminau J, Steenhoff D, Coletta A, Meganck S, Lazar C, de Schaetzen V, et al. inSilicoDb: an R\/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO. Bioinformatics. 2011;27:3204\u20135.","journal-title":"Bioinformatics"},{"key":"4264_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1544-6115.1027","volume":"3","author":"GK Smyth","year":"2004","unstructured":"Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:1.","journal-title":"Stat Appl Genet Mol Biol."},{"key":"4264_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9:811\u20138.","journal-title":"Stat Med"},{"issue":"18","key":"4264_CR33","first-page":"30124","volume":"S0090\u20138258","author":"S Lheureux","year":"2018","unstructured":"Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: a NCI clinical trials planning meeting report. Gynecol Oncol. 2018;S0090\u20138258(18):30124.","journal-title":"Gynecol Oncol"},{"key":"4264_CR34","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"4264_CR35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41416-018-0309-1","volume":"119","author":"F Bertucci","year":"2018","unstructured":"Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, et al. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer. 2018;119:1383\u201391.","journal-title":"Br J Cancer"},{"key":"4264_CR36","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","volume":"7","author":"L Malorni","year":"2016","unstructured":"Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, et al. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget. 2016;7:68012\u201322.","journal-title":"Oncotarget"},{"key":"4264_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4: e297.","journal-title":"PLoS Med"},{"key":"4264_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","volume":"31","author":"N Concin","year":"2021","unstructured":"Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12\u201339.","journal-title":"Int J Gynecol Cancer"},{"key":"4264_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","volume":"7","author":"V Makker","year":"2021","unstructured":"Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7:88.","journal-title":"Nat Rev Dis Primers"},{"key":"4264_CR40","doi-asserted-by":"crossref","unstructured":"Colombo N, Creutzberg C, Amant F, Bosse T, Gonz\u00e1lez-Mart\u00edn A, Ledermann J, et al (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer diagnosis, treatment and follow-up. Annals of Oncology. 27: 16\u201341.","DOI":"10.1093\/annonc\/mdv484"},{"key":"4264_CR41","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/jog.15247","volume":"48","author":"S Yuce Sari","year":"2022","unstructured":"Yuce Sari S, Guler OC, Oymak E, Gultekin M, Yigit E, Kahvecioglu A, et al. Uterine papillary serous and clear cell carcinomas: comparison of characteristics and clinical outcomes. J Obstet Gynaecol Res. 2022;48:1876\u201387.","journal-title":"J Obstet Gynaecol Res"},{"key":"4264_CR42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cjp2.109","volume":"4","author":"PF Rambau","year":"2018","unstructured":"Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian tumor tissue analysis consortium study. J Pathol Clin Res. 2018;4:250\u201361.","journal-title":"J Pathol Clin Res"},{"key":"4264_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253472","volume":"16","author":"A Pasanen","year":"2021","unstructured":"Pasanen A, Loukovaara M, Ahvenainen T, Vahteristo P, B\u00fctzow R. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma. PLoS ONE. 2021;16: e0253472.","journal-title":"PLoS ONE"},{"key":"4264_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","volume":"158","author":"SR Kim","year":"2020","unstructured":"Kim SR, Cloutier BT, Leung S, Cochrane D, Britton H, Pina A, et al. Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification. Gynecol Oncol. 2020;158:3\u201311.","journal-title":"Gynecol Oncol"},{"key":"4264_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/PGP.0000000000000369","volume":"36","author":"M K\u00f6bel","year":"2017","unstructured":"K\u00f6bel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, et al. Frequent mismatch repair protein deficiency in mixed endometrioid and clear cell carcinoma of the endometrium. Int J Gynecol Pathol. 2017;36:555\u201361.","journal-title":"Int J Gynecol Pathol"},{"key":"4264_CR46","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ygyno.2021.07.007","volume":"162","author":"A Travaglino","year":"2021","unstructured":"Travaglino A, Raffone A, Santoro A, Raimondo D, Angelico G, Valente M, et al. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: a systematic review and meta-analysis. Gynecol Oncol. 2021;162:804\u20138.","journal-title":"Gynecol Oncol"},{"key":"4264_CR47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/path.4947","volume":"243","author":"DF DeLair","year":"2017","unstructured":"DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol. 2017;243:230\u201341.","journal-title":"J Pathol"},{"issue":"Suppl 1","key":"4264_CR48","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","volume":"38","author":"R Murali","year":"2019","unstructured":"Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019;38(Suppl 1):S40-63.","journal-title":"Int J Gynecol Pathol"},{"key":"4264_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6741","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6741.","journal-title":"JAMA Oncol"},{"key":"4264_CR50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.04.13.21255421","author":"SN Westin","year":"2021","unstructured":"Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, et al. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1101\/2021.04.13.21255421.","journal-title":"Clin Cancer Res"},{"key":"4264_CR51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1047","author":"P Heudel","year":"2022","unstructured":"Heudel P, Frenel J-S, Dalban C, Bazan F, Joly F, Arnaud A, et al. Safety and efficacy of the mTOR inhibitor, vistusertib, combined with anastrozole in patients with hormone receptor-positive recurrent or metastatic endometrial cancer: the VICTORIA multicenter, open-LABEL, phase 1\/2 randomized clinical trial. JAMA Oncol. 2022. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1047.","journal-title":"JAMA Oncol"},{"key":"4264_CR52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","volume":"8","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol. 2022;8:1317\u201322.","journal-title":"JAMA Oncol"},{"key":"4264_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev-pathmechdis-012418-012917","volume":"15","author":"Y Wang","year":"2020","unstructured":"Wang Y, Hoang L, Ji JX, Huntsman DG. SWI\/SNF complex mutations in gynecologic cancers: molecular mechanisms and models. Annu Rev Pathol. 2020;15:467\u201392.","journal-title":"Annu Rev Pathol"},{"key":"4264_CR54","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532\u201343.","journal-title":"N Engl J Med"},{"key":"4264_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40661-017-0052-y","volume":"4","author":"JK Alldredge","year":"2017","unstructured":"Alldredge JK, Eskander RN. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol Oncol Res Pract. 2017;4:17.","journal-title":"Gynecol Oncol Res Pract"},{"key":"4264_CR56","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","volume":"31","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI). Int J Gynecol Cancer. 2021;31:1471\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"4264_CR57","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol. 2018;36:2044\u201351.","journal-title":"J Clin Oncol"},{"key":"4264_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3892\/mco.2020.2181","volume":"14","author":"OO Gordeeva","year":"2021","unstructured":"Gordeeva OO, Meshcheryakova LA, Karseladze AI, Meshcheryakova NA, Meshcheryakov AA. Combined anti-HER2 and hormonal treatment in a patient with HR+HER2+ clear-cell uterine carcinoma: a case report. Mol Clin Oncol. 2021;14:19.","journal-title":"Mol Clin Oncol"},{"key":"4264_CR59","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","volume":"6","author":"I Ray-Coquard","year":"2020","unstructured":"Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial. JAMA Oncol. 2020;6:1923\u201330.","journal-title":"JAMA Oncol"},{"key":"4264_CR60","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/COC.0000000000000277","volume":"41","author":"CN Chang-Halpenny","year":"2018","unstructured":"Chang-Halpenny CN, Natarajan S, Hwang-Graziano JM. Early-stage uterine pure and mixed clear cell carcinoma: outcomes and recurrence with and without adjuvant therapy. Am J Clin Oncol. 2018;41:371\u20138.","journal-title":"Am J Clin Oncol"},{"key":"4264_CR61","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29:1895\u2013902.","journal-title":"Ann Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04264-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T08:57:10Z","timestamp":1687510630000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4264"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04264-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients have been informed that their data could be used for further research studies. For biological analyzes, they should have personally signed and dated informed consent (whether TRMG network or institutional consents).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests that could have influenced this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}